DZNep (3-Deazaneplanocin A, NSC617989) is an S-adenosylhomocysteine hydrolase inhibitor, indirectly inhibiting histone methyltransferases and decreasing global DNA methylation. It competitively inhibits S-adenosylhomocysteine hydrolase (Ki ~50 pM), decreases EZH2 activities, and inhibits trimethylation of lysine 27 on histone H3 in cultured human acute myeloid leukemia (AML) HL-60 and OCI-AML3 cells and in primary AML cells in a dose-dependent manner (IC50?~0.2-1 μM). In vivo it shows strong anticancer activity by IP injection alone or in combination with the pan-histone deacetylase inhibitor panobinostat. DZNep can also enhance Oct 4 expression in generating induced pluripotent stem cells (iPSCs).
How to Use:
In vitro:? DZNep was used at 1 μM final concentration in vitro and in cellular assays.
In vivo: DZNep was IP or IV dosed to mice at 120 mg/kg once per day in the xenograft tumor model of Hep-G2, H358, A549, MDA-MB468, HCT116, CAL-27, HepG2, or HPAC.
?
Reference:
1. Tseng CK, et al. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. (1989) J Med Chem. 32(7):1442-6.
2. Tan J, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. (2007) Genes Dev. 21(9):1050-63.
3. Miranda TB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. (2009) Mol Cancer Ther. 8(6):1579-88.
4. He S, et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. (2012) Blood. 119(5):1274-82.
5. Hou P, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. (2013) Science. 341(6146):651-4.?
Products are for research use only. Not for human use.